⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Gilead added two new risk factors addressing climate change impacts and enterprise resource planning system implementation, while maintaining all 17 previously disclosed risks and substantively revising five existing disclosures. The most materially updated risk factors involved cybersecurity and data protection liabilities, global operational exposure, product litigation and government investigations, and clinical trial risks, reflecting heightened attention to digital infrastructure vulnerabilities and regulatory enforcement dynamics. No previously disclosed risks were eliminated, indicating Gilead's retention of its established risk management framework while expanding coverage of emerging threats.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟢 New in Current Filing Climate change and related natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations. 🔒

🟢 New in Current Filing The failure to successfully implement or upgrade enterprise resource planning and other information systems could adversely impact our business and results of operations. 🔒

🟡 Modified Information system service interruptions or breaches, including significant cybersecurity incidents, could give rise to legal liability and regulatory action under data protection and privacy laws and adversely affect our business and operations. 🔒

🟡 Modified We face risks associated with our global operations. 🔒

🟡 Modified We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations. 🔒

🟡 Modified We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption. 🔒

🟡 Modified Certain of our products subject us to additional or heightened risks. 🔒

7 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →